BSG Guideline: Diagnosis and management of patients at risk of gastric adenocarcinoma

British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma

Gastric adenocarcinoma continues to be a frequent cause of death in the world and is the 16th most common cancer in the UK. The most common stages in the progression to gastric adenocarcinoma are gastric atrophy (GA) and gastric intestinal metaplasia (GIM), which are collectively known as chronic atrophic gastritis (CAG). These conditions are principally caused by Helicobacter pylori infection and less commonly by autoimmune gastritis.

The key to having a significant impact on the prognosis of gastric adenocarcinoma and its economic burden is to accurately identify individuals at greatest risk and intervene with recognised efficacious treatments, including endoscopic resection, before cancer is established. The British Society of Gastroenterology (BSG) endoscopy committee agreed to create a guideline to provide statements and recommendations on the prevalence, risks, diagnosis, treatment, surveillance and screening of gastric premalignant and early gastric malignant lesions.

The principal patient group are those found to have GA, GIM, gastric epithelial dysplasia or early gastric adenocarcinoma limited to the mucosal or superficial submucosal layers. The target users include gastroenterologists, GI surgeons, pathologists, endoscopists and general practitioners.

http://dx.doi.org/10.1136/gutjnl-2018-318126

View the full document as a PDF here.

Read More

BSG logo
Endoscopy
Quality Improvement
British Society of Gastroenterology Endoscopic Retrograde Cholangiopancreatography (ERCP) Quality Improvement Programme: minimum service standards and good practice statements
clinical-resource/ERCP-Quality-Improvement-Programme
In 2014, the British Society of Gastroenterology (BSG) published a standards framework outlining key performance indicators for ERCP practitioners and services.

BSG logo
Guidance
AGIP
AGIP Proposed Standardised Testing Protocol for Hydrogen/Methane Breath Testing (HMBT) to Assess Small Intestinal Bacterial Overgrowth (SIBO) and Carbohydrate Malabsorption
clinical-resource/AGIP-Protocol-for-Hydrogen-Methane-Breath-Testing
This document was published in January 2019.